Brief: DiaMedica Therapeutics Files Complete Clinical Hold Response With FDA On Phase 2/3 Clinical Trial Of DM199

DiaMedica Therapeutics

22/05/2023 22:24

May 22 (Reuters) - DiaMedica Therapeutics Inc  DMAC.O :
    * DIAMEDICA THERAPEUTICS INC -  FILED ON MAY 19, A COMPLETE
CLINICAL HOLD RESPONSE WITH FDA FOR CLINICAL HOLD ON A PHASE 2/3
CLINICAL TRIAL OF DM199
    * DIAMEDICA THERAPEUTICS - CLINICAL HOLD RESPONSE WITH FDA
REQUESTING CLINICAL HOLD IMPOSED ON PHASE 2/3 CLINICAL TRIAL OF
DM199 FOR AIS BE LIFTED
    * DIAMEDICA THERAPEUTICS - INCLUDED IN RESPONSE TO FDA IS
PROTOCOL
AMENDMENT TO INCORPORATE REDUCED DOSE FOR INTRAVENOUS
ADMINISTRATION OF DM199
    * DIAMEDICA THERAPEUTICS INC - IN RESPONSE TO FDA, IS A
PROTOCOL
AMENDMENT TO INCORPORATE CERTAIN ADDED MEASURES TO REDUCE RISK
OF SEVERE HYPOTENSION

Further company coverage:  DMAC.O 

 ((Reuters.Briefs@thomsonreuters.com;))